Ratings CVS Health Corporation

Equities

CVS

US1266501006

Market Closed - Nyse 16:00:02 2024-05-21 EDT 5-day change 1st Jan Change
57.32 USD -0.14% Intraday chart for CVS Health Corporation +2.36% -27.41%

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.33 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-27.41% 71.96B
B-
+18.63% 84.11B
C+
+2.82% 27.25B
C+
-9.66% 17.31B
B
-2.17% 16.83B
A-
+3.96% 15.92B
A-
+7.75% 13.68B
B-
+72.83% 13.29B
C-
+72.50% 12.73B
C+
+32.39% 12.16B
B-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CVS Stock
  4. Ratings CVS Health Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW